“This study highlights that a substantial number of patients with localized CRC undergoing curative-intent treatment with CAPOX do not complete the planned cycles of chemotherapy because of toxicity ...

GEMSTONE-303 is the first trial demonstrating a statistically significant survival benefit for addition of an anti-PD-L1 antibody to standard chemotherapy for advanced gastric and gastroesophageal ...

Astellas Pharma’s strong pipeline and revenue growth support a positive outlook. See why ALPMF stock is a "Buy," driven by ...

APPLETON, Wis. (WBAY) - Colorectal cancer is the third-leading cause of cancer death for both men and women in the U.S., according to the American Cancer Society. March is Colorectal Cancer ...

All eyes are now on the readout of a second phase 3 trial called GLOW, looking at the addition of zolbetuximab to another chemo regimen called CAPOX in a similar population of treatment-naïve ...

The safety profile of sugemalimab with CAPOX was in line with previous research on anti ... The study authors concluded that the addition of sugemalimab to chemotherapy extended overall survival and ...

SHR-1701 plus CAPOX chemotherapy reduced treatment delays and dose reductions compared with placebo plus CAPOX in HER2-negative gastric/GEJ cancer.